The European Commission has implemented an export authorization scheme for SARS-COV-2 vaccines covering drugs bought under the Accelerated Purchase Program. That follows a delay in ramping up shipments from AstraZeneca even as the firm’s U.K. plant ran as expected. While the measure is not an export ban per se it is likely to drive a new round of medical protectionism. The U.S. and China accounted for 44.5% and 11.1% respectively of the EU’s vaccine exports in the 12 months to Oct. 31. Exports of vaccines to the U.K., mostly linked to seasonal flu, declined by 61.6% year o...